Tag archive for ‘Makena subcu dosage form launch’
Antares: Xyosted is Approved; Let the Good Times Roll (ATRS, Buy, $3.77)
Investment Thesis At Last, Three Major Product Approvals in 2018 It has been a torturous wait for Antares’ very promising pipeline to advance to commercialization, but the time has finally come. Antares and its partner Teva received approval for an AB rated generic to EpiPen on August 16, 2018 and Antares and its partner AMAG […]